Misplaced Pages

This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Active metabolite" – news · newspapers · books · scholar · JSTOR (January 2023) (Learn how and when to remove this message)

An active metabolite, or pharmacologically active metabolite is a biologically active metabolite of a xenobiotic substance, such as a drug or environmental chemical. Active metabolites may produce therapeutic effects, as well as harmful effects.

Metabolites of drugs

An active metabolite results when a drug is metabolized by the body into a modified form which produces effects in the body. Usually these effects are similar to those of the parent drug but weaker, although they can still be significant (see e.g. 11-hydroxy-THC, morphine-6-glucuronide). Certain drugs such as codeine and tramadol have metabolites (morphine and O-desmethyltramadol respectively) that are stronger than the parent drug and in these cases the metabolite may be responsible for much of the therapeutic action of the parent drug. Sometimes, however, metabolites may produce toxic effects and patients must be monitored carefully to ensure they do not build up in the body. This is an issue with some well-known drugs, such as pethidine (meperidine) and dextropropoxyphene.

Prodrugs

Sometimes drugs are formulated in an inactive form that is designed to break down inside the body to form the active drug. These are called prodrugs. The reasons for this type of formulation may be because the drug is more stable during manufacture and storage as the prodrug form, or because the prodrug is better absorbed by the body or has superior pharmacokinetics (e.g., lisdexamphetamine).

References

1. Fura, Aberra (February 2006). "Role of pharmacologically active metabolites in drug discovery and development". Drug Discovery Today. 11 (3–4): 133–142. doi:10.1016/S1359-6446(05)03681-0.
2. Haffen E, Paintaud G, Berard M, Masuyer C, Bechtel Y, Bechtel PR (June 2000). "On the assessment of drug metabolism by assays of codeine and its main metabolites". Therapeutic Drug Monitoring. 22 (3): 258–65. doi:10.1097/00007691-200006000-00005. PMID 10850391.
3. Raffa RB (July 1996). "A novel approach to the pharmacology of analgesics". The American Journal of Medicine. 101 (1A): 40S–46S. doi:10.1016/s0002-9343(96)00137-4. PMID 8764759.
4. ^ Zhou SF, Zhou ZW, Yang LP, Cai JP (2009). "Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development". Current Medicinal Chemistry. 16 (27): 3480–675. doi:10.2174/092986709789057635. PMID 19515014.
5. Coller JK, Christrup LL, Somogyi AA (February 2009). "Role of active metabolites in the use of opioids". European Journal of Clinical Pharmacology. 65 (2): 121–39. doi:10.1007/s00228-008-0570-y. PMID 18958460. S2CID 9977741.
6. Müller CE (November 2009). "Prodrug approaches for enhancing the bioavailability of drugs with low solubility". Chemistry & Biodiversity. 6 (11): 2071–83. doi:10.1002/cbdv.200900114. PMID 19937841. S2CID 32513471.

Further reading

• Nedderman, Angus N.R. & Walker, Don K. (2011). "Metabolite testing in drug development". In Bonate, Peter L. (ed.). Pharmacokinetics in Drug Development: Advances and Applications, Volume 3. Springer. ISBN 9781441979360.

• Pharmacokinetics
• Metabolism